Top

Nuhad K. Ibrahim

Department of Breast Medical Oncology, Division of Cancer Medicine

Present Title & Affiliation

Primary Appointment

Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

Vaccine in breast cancer, breast geriatric oncology, treatment of resistant breast cancer

Education & Training

Degree-Granting Education

1980	Baghdad Medical College, Baghdad, IQ, MD
1975	American University of Beirut, Beirut, LB, Biology-Chemistry, BS

Postgraduate Training

1992-1994	Project Investigator: Exploring c-ErbB-2 oncogene effect on tumorigenicity and drug resistance of lung and breast cancer cell lines, The University of Texas MD Anderson Cancer Center, Houston, Texas
1991-1994	Postdoctoral Fellowship in Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
1990-1991	PGYIII-Resident in Internal Medicine, St. Luke's-Roosevelt Hospital, New York, New York
1988-1990	PGYI & PGYII-Resident in Internal Medicine, SUNY Health Science Center, Brooklyn, New York
1983-1986	Fellow in Clinical Hematology-Oncology, American University of Beirut Medical Center, Beirut
1981-1983	Resident in General Surgery, American University of Beirut Medical Center, Beirut
1980-1981	Straight Surgical Internship, American University of Beirut Medical Center, Beirut

Board Certifications

1997	American Board of Medical Oncology
1994	American Board of Internal Medicine
1989	Federation Licensing Examination (FLEX)
1987	Foreign Medical Graduate Examination in the Medical Sciences (FMGEMS)

Experience & Service

Academic Appointments

Associate Professor, Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2001 - 2008

Assistant Professor, Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1995 - 2001

Junior Faculty Associate, Department of Medical Specialties, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1994 - 1995

Attending Physician, Department of Medical Oncology, Lebanese Cancer Center, Byblos, 1986 - 1987

Administrative Appointments/Responsibilities

Coordinator Breast Multidisciplinary Program, Department of Internal Medicine Section of Hematology and Oncology, The University of Texas Medical Branch, Galveston, TX, 2003 - 2005

Physician Auditor, Department of Office of Research Administration, Quality Assurance, The University of Texas MD Anderson Cancer Center, Houston, TX, 1998 - Present

Palliative Care Advisory Group, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1997 - 1999

Medical Compliance Liaison, Medicare Documentation and Education, Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1997 - 2000

Other Appointments/Responsibilities

Consultant, Athenex, Houston, 2020 - 2021

Advisory Board, Ipsen Bioscience, Houston, 2019 - 2019

Member, Advisory Committee for MDACC's Interpersonal Communication and Relationship Enhancement (I*CARE), Houston, TX, 2007 - 2007

Member, International Board Committee, Breast-Gynecological Cancer Society, Cairo, 2007 - 2007

Breast Committee, Southwest Oncology Group, Houston, TX, 2004 - 2005

Member, MDACC, Middle East Advisory Group, Houston, TX, 2004 - 2005

Oncology Consultant, Novartis Oncology, n/a, 2004 - 2005

Herceptin Advisory Board Consultant, Genentech Bio-Oncology, n/a, 2004 - 2005

Vice Chairman, MDACC Middle East Task Force, Houston, TX, 2003 - 2004

Therex Advisory Board, Antisoma, US, 2001 - 2004

Theratope Advisory Board, Biomera, n/a, 2000 - 2004

Telemedicine Breast and Multidisciplinary, MDACC Houston/MDACC Orlando, Houston, TX, 1998 - 2009

Member, Breast Cancer Research Group, n/a, 1995 - Present

Institutional Committee Activities

Member, Professional Liability Committee, 2019 - 2020

Vice Chair, Institutional Review Board II, 2019 - Present

Associate Member, Institutional Review Board I, 2017 - Present

Vice Chair, Institutional Review Board I, 2016 - Present

Member, Executive Institutional Review Board III, 2016 - Present

Member, Professional Liability Committee, 2015 - 2015

Member, Clinical Faculty Review Committee, 2015 - 2018

Member, Institutional Review Board I, 2014 - 2017

Coordinator, Breast Immunotherapy Research Group, 2013 - Present

Associate Member, Institutional Review Board I, 2013 - 2014

Breast Medical Oncology Representative, Credentials Committee of the Medical Staff Office, 2013 - 2016

Member, MD Anderson Physician Relations Peer-to-Peer Consultant, 2013 - Present

Member, Institutional Immunology Work Group, 2013 - Present

Member, Ongoing Professional Practice Evaluation Subcommittee, 2013 - Present

Alternative Department Representative, Credentials Committee of the Medical Staff, 2012 - 2013

Organizer, Breast Cancer Clinical Research Steering Committee, 2012 - Present

Member, Ongoing Protocol Performance Evaluation, 2012 - Present

Advisory Committee Member, Interpersonal Communication and Relationship Enhancement program, 2010 - Present

Steering Committee Member, Sister Institution relationship between MDACC and the Faculty of Medicine and Medical Center of the American University of Beirut, 2010 - Present

Alternative Department Representative, Credentials Committee of the Medical Staff, 2007 - 2010

Member, Steering committee for the Sister Institution relationship between M. D. Anderson Cancer Center and the Faculty of Medicine and Medical Center of the American University of Beirut, 2007 - Present

Chair-elect, Breast Medical Oncology Department Protocol and Concept Review Committee (Chair 2008-09), 2007 - 2008

Member, US-Middle East Breast Cancer Awareness & Research Committee, 2007 - Present

Vice Chair, Office of Research Administration, IRB II Committee, 2005 - 2009

Member, Institutional Research Grants Program Study Section Review Committee for Clinical Translational and Population-Based Research Projects, 2005 - Present

Associate Member, Institutional Review Board III, 2005 - Present

Member, Surveillance (IRB) Committee, Office of Research Administration, 2002 - 2009

Chairperson, Clinical Research Committee II, Office of Research Administration, 2001 - 2004

Member, Scientific Advisory Board, Office of Research Administration, 2001 - 2004

Representative, Faculty Senate, Breast Medical Oncology, 2000 - 2003

Member, Clinical Research Committee, Office of Research Administration, 1998 - 2001

Honors & Awards

	Travel Award, American Society of Clinical Oncology
	Who's Who in the South and the Southwest 24th edition
	Who's Who in the South and Southwest 25th Edition
	Who's Who in America
	Who's Who in Medicine and Healthcare
	Fellow, American College of Physicians
	Fellow, American Board of Hospital Physicians (HON)
	American College of Ethical Physicians (HON)
	Who's Who in the World 20th Edition
	Breast Medical Oncology Certificate of Appreciation (Highest Total Funding from Private Industry Contracts) Fiscal Year
	Best Doctors in America
	Breast Medical Oncology Certificate of Appreciation (Highest number of New Patients and Consults per percent of Effort) Fiscal Year
	Cambridge Who's Who
	Master of the American College of Ethical Physicians, American College of Ethical Physicians
	Who's Who in America
	Multi-Year Appointment Award
	Top Oncologist, The Leading Physicians of the World
	Top Oncologist, International Association of Oncologists

Professional Memberships

University of Texas MD Anderson Cancer Center

Mentor to Dr. Humaid Al-Shamsi, Visiting Professor, 2016 - 2016

The Africa Middle East Canter Intergroup

Steering Committee, 2016 - Present

Brain Metastases Institutional Working Group

Co-Leader, 2016 - Present

ASCO

Ambassador, 2014 - Present

Selected Publications

Peer-Reviewed Articles

Lin NU, Kumthekar P, Sahebjam S, Ibrahim N, Fung A, Cheng A, Nicholas A, Sussell J, Pegram M. Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data. NPJ Breast Cancer 9(1):94, 2023. e-Pub 2023. PMID: 37978197.
Akkoc Mustafayev FN, Liu DD, Gutierrez AM, Lewis JE, Ibrahim NK, Valero V, Booser DJ, Litton JK, Koenig K, Yu D, Sneige N, Arun BK. Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor-Negative Breast Cancer Chemoprevention. Eur J Breast Health 19(4):267-273, 2023. e-Pub 2023. PMID: 37795002.
Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul S, Moore JA, Yilmaz B, Ogbonna D, Karp DD, Dumbrava E, Tsimberidou AM, Hong DS, Rodon Ahnert J, Milton DR, Zheng X, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Cancer 129(14):2201-2213, 2023. e-Pub 2023. PMID: 37016732.
Tsimberidou AM, Guenther K, Andersson BS, Mendrzyk R, Alpert A, Wagner C, Nowak A, Aslan K, Satelli A, Richter F, Kuttruff-Coqui S, Schoor O, Fritsche J, Coughlin Z, Mohamed AS, Sieger K, Norris B, Ort R, Beck J, Vo HH, Hoffgaard F, Ruh M, Backert L, Wistuba II, Fuhrmann D, Ibrahim NK, Morris VK, Kee BK, Halperin DM, Nogueras-Gonzalez GM, Kebriaei P, Shpall EJ, Vining D, Hwu P, Singh H, Reinhardt C, Britten CM, Hilf N, Weinschenk T, Maurer D, Walter S. Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer. Cancer Immunol Res 11(7):925-945, 2023. PMID: 37172100.
Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson AM, Mittendorf EA, Adrada BE, Damodaran S, Virani K, White J, Ravenberg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmans WF, Litton JK, Tripathy D, Moulder S, Huo L. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel) 15(13), 2023. e-Pub 2023. PMID: 37444385.
Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JK. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat 199(3):457-469, 2023. e-Pub 2023. PMID: 37061619.
Chen H, Ding Q, Khazai L, Zhao L, Damodaran S, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Lim B, Thompson AM, Mittendorf EA, Adrada B, Virani K, White JB, Ravenberg E, Song X, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Routbort MJ, Sahin A, Valero V, Symmans WF, Tripathy D, Wang WL, Moulder S, Huo L. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol 15:17588359231189422, 2023. e-Pub 2023. PMID: 37547448.
Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J, Investigators A. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol 8(7):1047-1052, 2022. e-Pub 2022. PMID: 35552364.
Garber HR, Raghavendra AS, Lehner M, Qiao W, Gutierrez-Barrera AM, Tripathy D, Arun B, Ibrahim NK. Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer. NPJ Breast Cancer 8(1):46, 2022. e-Pub 2022. PMID: 35393462.
Singareeka Raghavendra A, Kypriotakis G, Karam-Hage M, Kim S, Jizzini M, Seoudy KS, Robinson JD, Barcenas CH, Cinciripini PM, Tripathy D, Ibrahim NK. The Impact of Treatment for Smoking on Breast Cancer Patients' Survival. Cancers (Basel) 14(6), 2022. e-Pub 2022. PMID: 35326615.
Abuhadra NK, Sun R, Litton J, Rauch GM, Yam C, Chang JT, Seth S, Bassett Jr R, Lim B, Thompson A, Mittendorf EA, Adrada BE, Damodaran S, White JB, Ravenberg EE, Candelaria RP, Arun BK, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim NK, Sahin AA, Valero V, Symmans WF, Tripathy D, Moulder S, Huo L. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers 14(5), 2022. PMID: 35267631.
Abuhadra N, Sun R, Litton JK, Seth S, Basset Jr R, Murthy RK, Ibrahim NK, Lim B, Thompson AM, Mittendorf E, Adrada BE, Damodaran D, White J, Ravenberg E, Candelaria R, Santiago L, Saleem S. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancerin Early-Stage Triple-Negative Breast Cancer. Cancers, 2022. PMID: None.
Goldstein LJ, Mansutti M, Levy C, Chang J, Henry S, Fernandez-Perez I, Prausova J, Staroslawska E, Viale G, Butler B, McCanna S, Ruffini PA, Wicha MS, Schott AF, Alvarez RH, Abu-Khalaf M, Ibrahim NK, Daniel B, Meshad,M, Kanamori D, Zelnak A, Graham M, Comer J, Huizing M, Duhoux FP, Richard V, Verhoeven D, Smakal M, Krasenska M, Kohoutek M, Zimovjanova M, Kubala E, Campone M, Ferrero JM, Gonçalvès A, Vénat-Bouvet L, Medioni J, Biganzoli L, Soto Parra H, Pedrazzoli P, Colleoni M, Moroni M, Amadori D, Morandi P, Cinieri S, Tomczak P, Sarosiek T, Wojtukiewicz MZ, Mruk A, Kukielka-Budny B. A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida). Breast Cancer Research and Treatment 190(2):265-275, 2021. PMID: 34476645.
Al-Shamsi HO, Abu-Gheida I, Abdulsamad AS, AlAwadhi A, Alrawi S, Musallam KM, Arun B, Ibrahim NK. Molecular Spectra and Frequency Patterns of Somatic Mutations in Arab Women with Breast Cancer. Oncologist 26(11):e2086-e2089, 2021. e-Pub 2021. PMID: 34327780.
Kai M, Marx AN, Liu DD, Shen Y, Gao H, Reuben JM, Whitman G, Krishnamurthy S, Ross MI, Litton JK, Lim B, Ibrahim N, Kogawa T, Ueno NT. A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer. Sci Rep 11(1):22242, 2021. e-Pub 2021. PMID: 34782633.
Lin NU, Pegram M, Sahebjam S, Ibrahim N, Fung A, Cheng A, Nicholas A, Kirschbrown W, Kumthekar P. Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study. J Clin Oncol 39(24):2667-2675, 2021. e-Pub 2021. PMID: 33945296.
Singareeka Raghavendra A, Alameddine HF, Andersen CR, Selber JC, Brewster AM, Barcenas CH, Caudle AS, Arun BK, Tripathy D, Ibrahim NK. Influencers of the Decision to Undergo Contralateral Prophylactic Mastectomy among Women with Unilateral Breast Cancer. Cancers (Basel) 13(9), 2021. e-Pub 2021. PMID: 33922702.
Ballhausen A, Wheler JJ, Karp DD, Piha-Paul SA, Fu S, Pant S, Tsimberidou AM, Hong DS, Subbiah V, Holley VR, Huang HJ, Brewster AM, Koenig KB, Ibrahim NK, Meric-Bernstam F, Janku F. Phase I study of everolimus, letrozole, and trastuzumab in patients with hormone receptor-positive metastatic breast cancer or other solid tumors. Clin Cancer Res 27(DOI: 10.1158/1078-0432.CCR-20-2878):1247-1255, 2021. e-Pub 2020. PMID: 33115815.
Alhalabi O, Soomro Z, Sun R, Hasanov E, Albittar A, Tripathy D, Valero V, Ibrahim NK. Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases. NPJ Breast Cancer 7(1):28, 2021. e-Pub 2021. PMID: 33742001.
Gao C, Wang F, Suki D, Strom E, Li J, Sawaya R, Hsu L, Raghavendra A, Tripathy D, Ibrahim NK. Effects of systemic therapy and local therapy on outcomes of 873 breast cancer patients with metastatic breast cancer to brain: MD Anderson Cancer Center experience. Int J Cancer 148(4):961-970, 2021. e-Pub 2020. PMID: 32748402.
Lim B, Song J, Ibrahim NK, Koenig KB, Chavez-MacGregor M, Ensor JE, Gomez JS, Krishnamurthy S, Caudle AS, Shaitelman SF, Whitman GJ, Valero V. A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. Oncologist 26(DOI: 10.1002/onco.13581):e230-e240, 2021. e-Pub 2020. PMID: 33140515.
Mariotti V, Han H, Ismail-Khan R, Tang SC, Dillon P, Montero AJ, Poklepovic A, Melin S, Ibrahim NK, Kennedy E, Vahanian N, Link C, Tennant L, Schuster S, Smith C, Danciu O, Gilman P, Soliman H. Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol 7(DOI: 10.1001/jamaoncol.2020.5572):61-69, 2021. e-Pub 2020. PMID: 33151286.
Bashour SI, Ibrahim NK, Schomer DF, Hess KR, Gao C, Tripathy D, Fuller GN. Central nervous system miliary metastasis in breast cancer: a case series analysis and proposed identification criteria of a rare metastasis subtype. Br J Cancer. e-Pub 2020. PMID: 32747747.
Freedman RA, Gelman RS, Agar NYR, Santagata S, Randall EC, Gimenez-Cassina Lopez B, Connolly RM, Dunn IF, Van Poznak CH, Anders CK, Melisko ME, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Moy B, Blackwell KL, Puhalla SL, Ibrahim N, Moynihan TJ, Nangia J, Tung N, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU, Research Consortium TBC. Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clin Breast Cancer 20(2):145-151.e2, 2020. e-Pub 2019. PMID: 31558424.
Al-Shamsi HO, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Meyers BM, Elfiki T, Curigliano G, Eng C, Grothey A, Xie C. A Practical Approach to the Management of Cancer Patients during the Novel Coronavirus Disease 2019 (COVID-19) Pandemic - An International Collaborative Group. Oncologist. e-Pub 2020. PMID: 32243668.
Ueno NT, Tahara RK, Fujii T, Reuben JM, Gao H, Saigal B, Lucci A, Iwase T, Ibrahim NK, Damodaran S, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, Lim B, Chasen BA. Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer. Cancer Med 9(3):1025-1032, 2020. e-Pub 2019. PMID: 31849202.
Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worms H, Moulder SL, Arun BK. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol 38(5):388-394, 2020. e-Pub 2019. PMID: 31461380.
Kumthekar P, Tang SC, Brenner A, Kesari S, Picioni D, Anders C, Carrillo J, Chlasani P, Kabos P, Puhalla S, Tkaczuk K, Garcia A, Ahluwalia M, Wefel J, Lakhani N, Ibrahim N. ANG1005, a brain penetrating peptide-drug conjugate shows activity in patients with brain cancer with leptomeningeal carcinomatosis and recurrent brain metastases. Clinical Cancer Research(CCR-19-3258), 2020. PMID: None.
Kettner NM, Vijayaraghavan S, Durak MG, Bui T, Kohansal M, Ha MJ, Liu B, Rao X, Wang J, Yi M, Carey JPW, Chen X, Eckols TK, Raghavendra AS, Ibrahim NK, Karuturi MS, Watowich SS, Sahin A, Tweardy DJ, Hunt KK, Tripathy D, Keyomarsi K. Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer. Clin Cancer Res 25(13):3996-4013, 2019. e-Pub 2019. PMID: 30867218.
Lim B, Murthy RK, Lee J, Jackson SA, Iwase T, Davis DW, Willey JS, Wu J, Shen Y, Tripathy D, Alvarez R, Ibrahim NK, Brewster AM, Barcenas CH, Brown PH, Giordano SH, Moulder SL, Booser DJ, Moscow JA, Piekarz R, Valero V, Ueno NT. A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. Br J Cancer 120(12):1105-1112, 2019. e-Pub 2019. PMID: 31097774.
Freedman RA, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, COmponeshi KP, Marte JM, Connolly RM, Moy B, Van Poznak CH, Blackwell KL, Puhalla SL, Jankowitz RC, Smith KL, Ibrahim N, Moynihan TJ, O'Sullivan CC, Nangia J, Niravath P, TUng N, Pohlmann PR, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. A Phase II Trial of Neratinib and Capecitabine for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases. JCO, 2019. PMID: None.
Freedman RA, Gelman Rebecca S, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Connolly RM, Moy B, Poznak CH, Blackwell KL, Puhalla SL, Jankowitz RC, Smith KL, Ibrahim N, Moynihan TJ, O'Sullivan CC, Nangia J, Niravath P, Tung N, Pohlmann PR, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients with Human Epidermal Growth Factor Receptor 2 - Positive Breast Cancer and Brain Metastases. JCO 37(13), 2019. PMID: None.
Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, Zhang J, Ibrahim NK, DeGroot JF, McCarty J, O'Brien BJ, Sawaya R, Verhaak RGW, Reddy SK, Priebe W, Gatalica Z, Spetzler D, Heimberger AB. Profiles of Brain Metastases: Prioritization of Therapeutic Targets. Int J Cancer 143(11):3019-3026, 2018. e-Pub 2018. PMID: 29923182.
Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, Arun BK, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, Ibrahim NK. Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer 124(11):2299-2305, 2018. e-Pub 2018. PMID: 29579338.
Al-Awadhi AM, Murray JL, Ibrahim NK. Developing Anti–HER-2 Vaccines: Breast Cancer Experience. International Journal of Cancer, 2018. PMID: None.
Weiss A, Bashour SI, Hess K, Thompson AM, Ibrahim NK. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy. Breast Cancer Res 20(1):27, 2018. e-Pub 2018. PMID: 29661243.
Bashour SI, Ibrahim NK, Schomer DF, Herr KR, Gao C, Tripathy D, Fuller GN. Central Nervous System Miliary Metatasis in Breast Cancer Patients. Cancer Research 78, 2018. PMID: None.
Clifton GT, Litton JK, Arrington K, Ponniah S, Ibrahim NK, Gall V, Alatrash G, Peoples GE, Mittendorf EA. Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients. Ann Surg Oncol 24(8):2161-2167, 2017. e-Pub 2017. PMID: 28315060.
Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Yi M, Raghavendra AS, Zhao Y, Bashour SI, Ibrahim NK, Karuturi M, Wang J, Winkler JD, Amaravadi RK, Hunt KK, Tripathy D, Keyomarsi K. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat Commun 8(15916):15916, 2017. e-Pub 2017. PMID: 28653662.
Chen S, Ibrahim NK, Yan Y, Wong ST, Wang H, Wong FC. Complete Metabolic Response on Interim 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. Oncologist 22(5):526-534, 2017. e-Pub 2017. PMID: 28377466.
Sneige N, Hess KR, Multani AS, Gong Y, Ibrahim NK. Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study. Cancer 123(7):1115-1123, 2017. e-Pub 2016. PMID: 27893937.
Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol 3(4):509-515, 2017. e-Pub 2016. PMID: 27893038.
Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, Litton JK, Koenig KB, Karuturi M, Abouharb S, Tripathy D, Moulder-Thompson SL, Ibrahim NK. Rapid breast cancer disease progression following cyclin dependent kinase 4 and 6 inhibitor discontinuation. J Cancer 8(11):2004-9, 2017. e-Pub 2017. PMID: 28819400.
Mitri Z, Nanda R, Blackwell K, Costelloe CM, Hood I, Wei C, Brewster AM, Ibrahim NK, Koenig KB, Hortobagyi GN, Van Poznak C, Rimawi MF, Moulder-Thompson S, Research Consortium TBC. TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis. Clin Cancer Res 22(23):5706-5712, 2016. e-Pub 2016. PMID: 27166393.
Farsaci B, Donahue RN, Grenga I, Lepone LM, Kim PS, Dempsey B, Siebert JC, Ibrahim NK, Madan RA, Heery CR, Gulley JL, Schlom J. Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. Cancer Immunol Res 4(9):755-65, 2016. e-Pub 2016. PMID: 27485137.
Arun BK, Gong Y, Liu D, Litton JK, Gutierrez-Barrera AM, Jack Lee J, Vornik L, Ibrahim NK, Cornelison T, Hortobagyi GN, Heckman-Stoddard BM, Koenig KB, Alvarez RR, Murray JL, Valero V, Lippman SM, Brown P, Sneige N. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Res Treat 158(1):67-77, 2016. e-Pub 2016. PMID: 27287781.
Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol 34(9):945-52, 2016. e-Pub 2016. PMID: 26834058.
Raghav K, French JT, Ueno NT, Lei X, Krishnamurthy S, Reuben JM, Valero V, Ibrahim NK. Inflammatory breast cancer: a distinct clinicopathological entity transcending histological distinction. PLoS One 11(1):e0145534, 2016. e-Pub 2016. PMID: 26752563.
Chen S, Ibrahim NK, Yan Y, Wong ST, Wang H, Wong FC. Risk stratification in patients with advanced-stage breast cancer by pretreatment [(18) F]FDG PET/CT. Cancer 121(22):3965-74, 2015. e-Pub 2015. PMID: 26249241.
Gonzalez-Angulo AM, Lei X, Alvarez RH, Green MC, Murray JL, Valero V, Koenig KB, Ibrahim NK, Litton JK, Nair L, Krishnamurthy S, Hortobagyi GN, Meric-Bernstam F. Phase II randomized study of ixabepilone versus observation in patients with significant residual disease after neoadjuvant systemic therapy for HER2-negative breast cancer. Clin Breast Cancer 15(5):325-31, 2015. e-Pub 2015. PMID: 25913905.
Heery CR, Ibrahim NK, Arlen PM, Mohebtash M, Murray JL, Koenig K, Madan RA, McMahon S, Marté JL, Steinberg SM, Donahue RN, Grenga I, Jochems C, Farsaci B, Folio L, Schlom J, Gulley JL. Docetaxel alone or in combination with a therapeutic cancer vaccine (PANVAC) in patients with metastatic breast cancer: a randomized clinical trial. JAMA Oncol. e-Pub 2015. PMID: 26291768.
Mitri Z, Karakas C, Wei C, Briones B, Simmons H, Ibrahim N, Alvarez R, Murray JL, Keyomarsi K, Moulder S. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Invest New Drugs 33(4):890-4, 2015. e-Pub 2015. PMID: 25947565.
Shen Q, Sahin AA, Hess KR, Suki D, Aldape KD, Sawaya R, Ibrahim NK. Breast cancer with brain metastases: clinicopathologic features, survival and paired biomarker analysis. Oncologist 20(5):466-73, 2015. e-Pub 2015. PMID: 25802405.
Bashour SI, Ibrahim NK. CCR 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxel-How Far Science Has Come. Clin Cancer Res 9:1975-7, 2015. PMID: 25934886.
Delpech Y, Lousquy R, Rouzier R, Hess K, Coutant C, Barranger E, Esteva FJ, Ueno NT, Pusztai L, Ibrahim NK. Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. Br J Cancer, 2015. e-Pub 2015. PMID: 26393887.
Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer . Ann Oncol 25(6):1122-7, 2014. e-Pub 2014. PMID: 24669015.
Abdayem P, Ghosn M, Valero V, Walters R, Arun B, Murray JL, Theriault R, Frye D, Ibrahim NK. Phase I and II study of gemcitabine and vinorelbine in heavily pretreated patients with metastatic breast cancer and review of the literature. J Cancer 5(5):351-9, 2014. e-Pub 2014. PMID: 24723978.
Bayraktar S, Gutierrez-Barrera AM, Lin H, Elsayegh N, Tasbas T, Litton JK, Ibrahim NK, Morrow PK, Green M, Valero V, Booser DJ, Hortobagyi GN, Arun BK. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. Clin Exp Metastasis 30(5):631-42, 2013. e-Pub 2013. PMID: 23370825.
Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat 137(2):631-6, 2013. e-Pub 2012. PMID: 23242617.
Ibrahim NK, Murray JL, Zhou D, Mittendorf EA, Sample D, Tautchin M, Miles D. Survival advantage in patients with metastatic breast cancer receiving endocrine therapy plus Sialyl Tn-KLH vaccine: post hoc analysis of a large randomized trial. J Cancer 4(7):577-584, 2013. e-Pub 2013. PMID: 23983823.
Yust-Katz S, Garciarena P, Liu D, Ibrahim NK, Penas-Prado M, Groves M. Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD but not survival. J Neurooncol 114:229-235, 2013. PMID: None.
Song W, Delyria ES, Chen J, Huang W, Lee JS, Mittendorf EA, Ibrahim N, Radvanyi LG, Li Y, Lu H, Xu H, Shi Y, Wang LX, Ross JA, Rodrigues SP, Almeida IC, Yang X, Qu J, Schocker NS, Michael K, Zhou D. MUC1 glycopeptide epitopes predicted by computational glycomics. Int J Oncol 41(6):1977-84, 2012. e-Pub 2012. PMID: 23023583.
Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU. Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol 30(9):930-5, 2012. e-Pub 2012. PMID: 22331946.
Ibrahim NK, Yariz KO, Bondarenko I, Manikhas A, Semiglazov V, Alyasova A, Komisarenko V, Shparyk Y, Murray JL, Jones D, Senderovich S, Chau A, Erlandsson F, Acton G, Pegram M. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Clin Cancer Res 17(21):6822-30, 2011. e-Pub 2011. PMID: 21878535.
Finn RS, Bengala C, Ibrahim N, Roché H, Sparano J, Strauss LC, Fairchild J, Sy O, Goldstein LJ. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res 17(21):6905-13, 2011. e-Pub 2011. PMID: 22028489.
Gerber DE, Stopeck AT, Wong L, Rosen LS, Thorpe PE, Shan JS, Ibrahim NK. Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 17(21):1-9, 2011. e-Pub 2011. PMID: 21989064.
Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305(18):1873-81, 2011. PMID: 21558518.
Arun BK, Dhinghra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin G, Walters R, Sahin A, Ibrahim N, Buzdar AU, Frye D, Sneige N, Strom E, Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GN. Phase III Randomized Trial of Dose Intensive Neoadjuvant Chemotherapy with or Without G-CSF in Locally Advanced Breast Cancer: Long-Term Results. Oncologist 16(11):1527-34, 2011. e-Pub 2011. PMID: 22042783.
Miles D, Roché H, Martin M, Perren TJ, Cameron DA, Glaspy J, Dodwell D, Parker J, Mayordomo J, Tres A, Murray JL, Ibrahim NK, Group TS. Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer. Oncologist 16(8):1092-1100, 2011. e-Pub 2011. PMID: 21572124.
Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-Figueroa LJ, Souchon E, Coutant C, Doimi FD, Ibrahim NK, Gong Y, Hortobagyi GN, Hess KR, Symmans WF, Pusztai L. Evaluation of a 30-gene Paclitaxel, Fluorouracil, Doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 16(21):5351-61, 2010. e-Pub 2010. PMID: 20829329.
Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol 28(28):4316-23, 2010. e-Pub 2010. PMID: 20805453.
Hortobagyi GN, Young RR, Karwal M, Ibrahim NK, Hermann R, Murray JL, Watkins SP, Gore I. A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer. Cancer 116(10):2301-6, 2010. e-Pub 2010. PMID: 20225231.
Graesslin O, Abdulkarim BS, Coutant C, Huguet F, Gabos Z, Hsu L, Marpeau O, Uzan S, Pusztai L, Strom EA, Hortobagyi GN, Rouzier R, Ibrahim NK. Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol 28(12):2032-7, 2010. e-Pub 2010. PMID: 20308667.
Royer B, Yin W, Pegram M, Ibrahim N, Villanueva C, Mir D, Erlandsson F, Pivot X. Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer. Br J Cancer 102(5):827-32, 2010. e-Pub 2010. PMID: 20160731.
Ibrahim NK. Ixabepilone Development Across the Breast Cancer Continuum: A Paradigm Shift. Cancer Manag Res 2:169-179, 2010. e-Pub 2010. PMID: 21188108.
Pegram MD, Borges V, Ibrahim N, Fuloria J, Shapiro C, Perez S, Wang K, Schaedeli Stark F, Courtenay Luck N. Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res 11(5):R73, 2009. e-Pub 2009. PMID: 19811637.
Shumway NM, Ibrahim N, Ponniah S, Peoples GE, Murray JL. Therapeutic Breast Cancer Vaccines: A New Strategy for Early-Stage Disease. BioDrugs 23(5):277-87, 2009. PMID: 19754218.
Estephan F, Valero V, Esteva FJ, Mejia JA, Frye DK, Ibrahim NK. Phase I Study of Prolonged-infusion Gemcitabine Combined with Cyclophosphamide in Patients with Metastatic Carcinoma of the Breast: Tolerability of an Optimal Dose Schedule. Oncology 77(1):63-70, 2009. e-Pub 2009. PMID: 19556811.
Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, Aldape KD, Yu TK, Hortobagyi GN, Gonzalez-Angulo AM. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 19(7):1242-8, 2008. e-Pub 2008. PMID: 18334512.
Kaur H, Loyer EM, David CL, Sawaf H, DuBrow RA, Ibrahim NK. Radiologic findings in taxane induced colitis. Eur J Radiol 66(1):75-8, 2008. e-Pub 2007. PMID: 17553645.
Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13(1):228-33, 2007. PMID: 17200359.
Motwani SB, Strom EA, Schechter NR, Butler CE, Lee GK, Langstein HN, Kronowitz SJ, Meric-Bernstam F, Ibrahim NK, Buchholz TA. The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys 66(1):76-82, 2006. e-Pub 2006. PMID: 16765534.
Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gomez HL, Hortobagyi GN, Pusztai L. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24:4236-44, 2006. PMID: 16896004.
Altundag K, Ibrahim NK. Aromatase inhibitors in breast cancer: an overview. Oncologist 11(6):553-62, 2006. PMID: 16794235.
Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23(25):5983-92, 2005. PMID: 16087943.
Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC, Nair MK, Bhar P, Desai N, Hortobagyi GN. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23:6019-26, 2005. PMID: 16135470.
Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, Fleming DR, Rouzier R, Boniface G, Hortobagyi GN. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104(4):682-91, 2005. PMID: 15986399.
Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11(16):5678-85, 2005. PMID: 16115903.
Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676-85, 2005. PMID: 15738535.
Li Z, Ibrahim NK, Wathen JK, Wang M, Mante Menchu RP, Valero V, Theriault R, Buzdar AU, Hortobagyi GN. Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. Cancer 101(7):1508-13, 2004. PMID: 15378497.
Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN, Pusztai L. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22(12):2284-93, 2004. PMID: 15136595.
Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25(3):94-102, 2004. PMID: 14698135.
Morandi P, Rouzier R, Altundag K, Buzdar A, Theriault R, Arun B, Booser D, Cristofanilli M, Esteva F, Gonzalez-Angulo A, Giordano S, Green M, Gwyn K, Ibrahim N, Murray J, Pusztai L, Rivera E, Thomas E, Valero V, Walters R, Bast R, Bevers T, Brewster A, Buchholz T, McNeese M, Strom E, Hortobagyi GN. The Role of Aromatase Inhibitors in the Adjuvant Treatment of Breast Cancer: MD Anderson Cancer Center Evidence Based Approach. Cancer 101 (7):1482-1489, 2004. PMID: None.
Trent JC, Valero V, Booser DJ, Esparza-Guerra LT, Ibrahim N, Rahman Z, Vernillet L, Patel S, David CL, Murray JL, Cristofanilli M, Hortobagyi GN. A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer. Clin Cancer Res 9(7):2426-34, 2003. PMID: 12855614.
Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, Buchholz TA, Krishnamurthy S, Ibrahim NK, Buzdar AU, Theriault RL, Rosales MF, Thomas ES, Gwyn KM, Green MC, Syed AR, Hortobagyi GN, Pusztai L. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer 97(12):2960-71, 2003. PMID: 12784330.
Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O'Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 21(6):1167-73, 2003. PMID: 12637486.
Giordano SH, Booser DJ, Murray JL, Ibrahim NK, Rahman ZU, Valero V, Theriault RL, Rosales MF, Rivera E, Frye D, Ewer M, Ordonez NG, Buzdar AU, Hortobagyi GN. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res 8(11):3360-8, 2002. PMID: 12429622.
Murray JL, Gillogly ME, Przepiorka D, Brewer H, Ibrahim NK, Booser DJ, Hortobagyi GN, Kudelka AP, Grabstein KH, Cheever MA, Ioannides CG. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 8(11):3407-18, 2002. PMID: 12429628.
Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8(5):1038-44, 2002. PMID: 12006516.
Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, Holmes FA, Hoy E, Frye DK, Manuel N, Kau SW, McNeese MD, Strom E, Thomas E, Hunt K, Ames F, Berry D, Hortobagyi GN. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 8:1073-9, 2002. PMID: 12006521.
Esmaeli B, Hortobagyi G, Esteva F, Valero V, Ahmadi MA, Booser D, Ibrahim N, Delpassand E, Arbuckle R. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol 13(2):218-21, 2002. PMID: 11885997.
Ibrahim NK, Rahman Z, Valero V, Murray JL, Frye D, Hortobagyi GN. Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. Cancer Invest 20(1):29-37, 2002. PMID: 11852999.
Cristofanilli M, Buzdar AU, Sneige N, Smith T, Wasaff B, Ibrahim N, Booser D, Rivera E, Murray JL, Valero V, Ueno N, Singletary ES, Hunt K, Strom E, McNeese M, Stelling C, Hortobagyi GN. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer 92(7):1775-82, 2001. PMID: 11745249.
Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 19(14):3422-3433, 2001. PMID: 11454891.
Ibrahim NK, Buzdar AU, Valero V, Dhingra K, Willey J, Hortobagyi GN. Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. Cancer 91(4):664-71, 2001. PMID: 11241232.
Ibrahim NK, Valero V, Rahman Z, Theriault RL, Walters RS, Buzdar AU, Booser DJ, Holmes FA, Murray JL, rd, Willey J, Bast R, Hortobagyi GN. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest 19(5):459-66, 2001. PMID: 11458813.
Ibrahim NK, Buzdar AU, Asmar L, Theriault RL, Hortobagyi GN. Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M. D. Anderson experience, with long-term follow-up. Ann Oncol 11(12):1597-601, 2000. PMID: 11205469.
Mandelblatt JS, Hadley J, Kerner JF, Schulman KA, Gold K, Dunmore-Griffith J, Edge S, Guadagnoli E, Lynch JJ, Meropol NJ, Weeks JC, Winn R. Patterns of breast carcinoma treatment in older women: patient preference and clinical and physical influences. Cancer 89(3):561-73, 2000. PMID: 10931455.
Ibrahim NK, Valero V, Theriault RL, Willey J, Walters RS, Buzdar AU, Booser DJ, Hortobagyi GN. Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer. Am J Clin Oncol 23(2):117-21, 2000. PMID: 10776969.
Ibrahim NK, Sahin AA, Dubrow RA, Lynch PM, Boehnke-Michaud L, Valero V, Buzdar AU, Hortobagyi GN. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet 355(9200):281-3, 2000. PMID: 10675076.
Edeiken BS, Fornage BD, Bedi DG, Singletary SE, Ibrahim NK, Strom EA, Holmes F. US-guided implantation of metallic markers for permanent localization of the tumor bed in patients with breast cancer who undergo preoperative chemotherapy. Radiology 213(3):895-900, 1999. PMID: 10580972.
Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, Smith TL, Asmar L, Frye D, Manuel N, Kau SW, McNeese M, Strom E, Hunt K, Ames F, Hortobagyi GN. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 17(11):3412-7, 1999. PMID: 10550135.
Ibrahim NK, Rahman Z, Valero V, Willey J, Theriault RL, Buzdar AU, Murray JL, rd, Bast R, Hortobagyi GN. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer 86(7):1251-7, 1999. PMID: 10506711.
Ibrahim NK, Hortobagyi GN, Ewer M, Ali MK, Asmar L, Theriault RL, Fraschini G, Frye DK, Buzdar AU. Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M. D. Anderson experience. Cancer Chemother Pharmacol 43(6):471-8, 1999. PMID: 10321507.
Yu D, Liu B, Jing T, Sun D, Price JE, Singletary SE, Ibrahim N, Hortobagyi GN, Hung MC. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene 16(16):2087-94, 1998. PMID: 9572489.
Hoff PM, Valero V, Ibrahim N, Willey J, Hortobagyi GN. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer 82(5):965-9, 1998. PMID: 9486588.
Ibrahim NK, Frye DK, Buzdar AU, Walters RS, Hortobagyi GN. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med 156(8):882-8, 1996. PMID: 8774207.
Shin HJC, Sneige N, Sahin A, Ibrahim NK, Atkinson EN. Glutathione S-Transferase-pi expression in prechemotherapy and post chemotherapy tumor samples from patients with locally advanced breast carcinomas. Breast 2:246-252, 1996. PMID: None.
Tsai CM, Yu D, Chang KT, Wu LH, Perng RP, Ibrahim NK, Hung MC. Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. J Natl Cancer Inst 87:682-4, 1995. PMID: 7538595.
Abdelnoor AM, Feghali CA, Abdelnour GE, Ibrahim N. Some immunological aspects in patients with breast carcinoma. Lebanese Science Bulletin, 1988. PMID: None.
Ibrahim NK, Khouri FP, Salem PA. VP-16-based regimen in adult acute nonlymphoblastic leukemia. Oncology 45:21-3, 1988. PMID: 3340391.
Saab GA, Ibrahim N, Azouri N. Efficacy of continuous high-dose metoclopramide in patients receiving daily cisplatin infusions. Cancer Treat Rep 71(10):979-80, 1987. PMID: 3652059.
Salem P, el-Hashimi L, Anaissie E, Geha S, Habboubi N, Ibrahim N, Khalyl M, Allam C. Primary small intestinal lymphoma in adults. A comparative study of IPSID versus non-IPSID in the Middle East. Cancer 59(9):1670-6, 1987. PMID: 3828967.
Salem P, Anaissie E, Allam C, Geha S, Hashimi L, Ibrahim N, Jabbour J, Habboubi N, Khalyl M. Non-Hodgkin's lymphomas in the Middle East. A study of 417 patients with emphasis on special features. Cancer 58(5):1162-6, 1986. PMID: 3731043.
Ibrahim NK, Abdul-Karim FW. Colorectal adenocarcinoma in young Lebanese adults. The American University of Beirut-Medical Center experience with 32 patients. Cancer 58(3):816-20, 1986. PMID: 3015371.
Ibrahim NK, Abdul-Karim FW. Colorectal adenocarcinoma in young Lebanese adults. The American University of Beirut-Medical Center experience with 32 patients. Cancer 58(3):816-20, 1986. PMID: 3015371.
Mokhbat, JE, Ibrahim NK, Abdul-Karim FW, Shatila MK, Salem ZM. The acquired immuno-deficiency syndrome (AIDS). Report of the First Case in Lebanon and a Review of the Literature. Lebanese Medical Journal 35:295, 1985. PMID: None.

Invited Articles

Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Dieras V, Muller V, Tagliaferri M, Hannan AL, Cortes J. ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases. Future Oncology, 2019. PMID: None.
Bashour SI, Ibrahim NK. CCR 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxel-How Far Science Has Come. Clin Cancer Res 21(9):1975-1977, 2015. PMID: 25934886.
Ibrahim NK. Clinical trials explore systemic treatments for brain metastases from breast cancer. OncoLog, 2015. PMID: None.
Shafaee MN, Ibrahim NK. Bavituimab. Phosphatidylserine-targeting MAb, Ligand-directed vascular disrupting agent. Drugs of the Future 40(5):281-286, 2015. PMID: None.
Pinder MC, Ibrahim NK. Nanoparticle albumin-bound paclitaxel for treatment of metastatic breast cancer. Drugs Today (Barc) 42(9):599-604, 2006. PMID: 17028669.
Ibrahim N. Aromatase Inhibitors in Breast Cancer: An Evidence-Based Paradigm. WebMD/Medscape, 2004. PMID: None.
Ibrahim NK, Murray JL. Clinical development of the STn-KLH vaccine (Theratope). Clin Breast Cancer 3 Suppl 4:S139-43, 2003. PMID: 12620151.
Ibrahim NK, Hortobagyi, GN. Taxane-Induced Colitis in Patients with Breast Cancer. Breast Diseases: A Year Book Quarterly 14 (2):118-120, 2003. PMID: None.
Ibrahim N. Theratope Vaccine Therapy Following Frontline Therapy for Metastatic Breast Cancer. Foundation of Clinical Cancer Research 2 (1), 2003. PMID: None.
Ibrahim N. Using Monoclonal Antibodies to Attenuate Chemo-resistance in LABC. Foundation of Clinical Cancer Research 2 (1), 2003. PMID: None.
Ibrahim N. The role of anti-tumor cancer vaccines. Associate Connection. Associate Connection (alumni publication of MD Anderson Associates) 2 (5):2, 2001. PMID: None.
Ibrahim NK, Hortobagyi GN. The evolving role of specific estrogen receptor modulators (SERMs). Surg Oncol 8:103-23, 1999. PMID: 10732962.
Ibrahim NK, Hortobagyi GN. New Antiestrogens in Breast Cancer: A Review. Breast J 4(4):213-219, 1998. PMID: 21223440.
Hortobagyi GN, Holmes FA, Ibrahim N, Champlin R, Buzdar AU. The University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancer. Semin Oncol 24 (Suppl 3):30-33, 1997. PMID: 9071338.
Hortobagyi GN, Ibrahim N. Paclitaxel-containing combination chemotherapy for metastatic breast cancer. Semin Oncol 23:53-7, 1996. PMID: 8629039.
Hortobagyi GN, Ibrahim N. Combinations of new and old agents for breast cancer treatment: future directions. Oncol 10:30-36, 1996. PMID: None.
Ibrahim N, Buzdar AU, Hortobagyi GN. Breast cancer in the elderly. Cancer Bull 47:212 -217, 1995. PMID: None.
Ibrahim NK, Foreman AD, Podoloff DA, Buzdar AU. Brachial plexopathy and porencephaly in a patient with breast cancer: case report and review of literature. Cancer Bull 46:185-188, 1994. PMID: None.
Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson AM, Mittendorf EA, Adrada B, Damodaran S, Virani K, White J, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim NK, Sahin A, Valero V, Fraser Symmans W, Litton JK, Tripathy D, Moulder S, Huo L. Predictive role of baseline stromal tumor-infiltrating lymphocytes and Ki-67 for pathologic complete response in an early-stage triple-negative breast cancer prospective trial. None. PMID: None.

Manuals, Teaching Aids, Other Teaching Publications

Alameddire H. Decision Making Process and Contralateral Prophylactic Mastectomy. A Dissertation in fulfillment of the requirement for the Degree of Doctor of Philosophy, Health Services- Community Health Education, March 2020. Advisor/Mentor: Nuhad K Ibrahim, MD, FACP.”. Walden University, 2020.
. Breast Cancer Treatment Pathways. None, 2013.
co-author IN. Breast Cancer Educational Pamphlet, Orlando - M. D. Anderson Cancer Center. None, 2002.
Michael Miller CWD. CD-ROM on Breast Reconstructive Surgery. None, 2002.

Editorials

Al-Shamsi HO, Ibrahim NK. The adddition of bevacizumab to neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer, more not necessarily better. Transl Cancer Res 5(4):S694-S696, 2016. PMID: None.
Boutros C, Mazouni C, Lerebours F, Stevens D, Lei X, Gonzalez-Angulo AM, Delaloge S. Commentary on "A preoperative nomogram to predict the risk of synchronous distant metastases at diagnosis of primary breast cancer". Br J Cancer 112(6):992-7, 2015. PMID: 25668007.
Ibrahim NK. Albumin-bound Paclitaxel in metastatic breast cancer: viewpoints. Drugs 66:949-50, 2006. PMID: 16740011.
Ibrahim NK. Leukemogenic effect of chemotherapy in patients with breast carcinoma: is it a real concern?. Cancer 101:1479-81, 2004. PMID: 15378475.
Ibrahim NK. Commentary on Amplification of erbB2 and erbB2 Expression Are Superior to Estrogen Receptor Status As Risk Factors for Distant Recurrence in pT1N0M0 Breast Cancer: A Nationwide Population-based Study. Breast Diseases: A Year Book Quarterly 14:302-303, 2003. PMID: None.
Ibrahim NK. Commentary on "A review of vinorelbine in the treatment of breast cancer". Clin Breast Cancer 2(3):236, 2001. PMID: 11899419.

Abstracts

Ibrahim NK, Raghavendra AS. Breast Cancer Brain Metastasis: A Comprehensive Review. American Society of Clinical Oncology, 2024. PMID: None.
Ibrahim NK. Anti-estrogen Therapy of Breast Cancer: A Complex Path from Genomic Targets to Resistance. International Conference on Molecular Oncology and Precision Medicine, 2023. PMID: None.
Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson AM, Mittendorf EA, Adrada BE, Damodaran S, Virani K, White J, Ravenberg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmans WF, Litton JK, Tripathy D, Moulder S, Huo L. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers 2023(15):3275, 2023. PMID: None.
Tsimberidou AM, Guenther K, Andersson BS, Mendrzyk R, Alpert A, Wagner C, Nowak A, Aslan K, Satelli A, Richter F, Kuttruff-Coqui S, Schoor O, Fritsche J, Coughlin Z, Mohamed AS, Sieger K, Norris B, Ort R, Beck J, Vo HH, Hoffgaard F, Ruh M, Backert L, Wistuba II, Fuhrmann D, Ibrahim NK, Morris VK, Kee BK, Halperin DM, Nogueras-González GM, Kebriaei P, Shpall EJ, Vining D, Hwu P, Singh-Jasuja H, Reinhardt C, Britten CM, Hilf N, Weinschenk T, Maurer D, Walter S. Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer. Cancer Immunology Research 11(7):925-945, 2023. e-Pub 2023. PMID: 37172100.
Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul S, Moore JA, Yilmaz B, Ogbonna D, Karp DD, Dumbrava E, Tsimberidou AM, Hong DS, Rodon Ahnert J, Milton DR, Zheng X, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. American Cancer Society:1-13. e-Pub 2023. PMID: 37016732.
Ibrahim NK, Arun B. BRCA1 or BRCA2 mutation variants in early breast cancer confer added prognostic information. J Cell Mol Immunol. 2023;2(1):1-5 2(1):1-5, 2023. PMID: None.
Damodaran S, Lu D, Schwartz-Gomer J, Valero V, Ramirez D, Saleem S, Ueno NT, Ibrahim NK, Karuturi M, Murthy RK, Sl M, Litton JK. A phase Ib trial of bintrafusp alfa and eribulin in patients with metastatic triple negative breast cancer (TNBC). San Antonio Breast Cancer Symposium 2022, 2022. PMID: None.
Hamilton E, Pusztai L, Soliman H, Hurvitz S, Grzegorzewski K, Habboubi N, Marreddy P, Sahmoud T, Ibrahim N. ELONA: An Open-Label, Phase 1b/2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor-Positive, Progesterone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer. San Antonio Breast Cancer Symposium 2022, 2022. PMID: None.
Damodaran S, Lu D, Schwartz-Gomez J, Valero V, Ramirez D, Saleem S, Ueno NT, Ibrahim NK, Karuturi M, Murthy RK, Moulder SL, Litton JK. A phase Ib trial of bintrafusp alfa and eribulin in patients with metastatic triple negative breast cancer (TNBC). San Antonio Breast Cancer Symposium 2022, 2022. PMID: None.
Yam C, Li Z, Korkut A, Ma W, Kong E, Hill HA, Abbas H, Abouharb S, Adrada B, Arun BK, Barcenas CH, Bisen A, Booser D, Buzdar A, Candelaria RP, Chen JJ, Clayborn A, Damodaran S, Ding QQ, Garber H, Hortobagyi GN, Hunt KK, Ibrahim NK, Iheme A, Karuturi MS, Koenig K, Layman RM, Lee J, Litton JK, Mitchell M, Moscol G, Mouabbi J, Murthy RK, Oke O, Pohlmann P, Ramirez D, Ravenberg E, Saleem S, Teshome M, Valero V, White J, Williams M, Woodward WA, Yajima C, Ueno NT, Chen K, Rauch GM, Huo L, Tripathy D. Clinical and Molecular Characteristics of HER2-Low/Zero, Early Stage Triple-Negative Breast Cancer. San Antonio Breast Cancer Symposium 2022, 2022. PMID: None.
Marx AN, Kai M, Fu M, Murphy HE, Willey JS, Sun H, Alexander A, Bassett RL, Whitman G, Le-Petross H, Patel M, Woodward W, Lucci A, Arun B, Abouharb S, Thomas P, Barcenas CH, Booser DJ, Ibrahim NK, Valero V, Ueno NT, Layman RM, Lim B. A phase 1b study of neratinib with THP in metastatic and locally advanced breast cancer, and phase II study of THP followed by AC in HER2 + primary inflammatory breast cancer (IBC), and neratinib with Taxol followed by AC in HR+ /HER2- primary IBC. San Antonio Breast Cancer Symposium 2022, 2022. PMID: None.
Ran A, Wang Y, Fuchenchu W, Gao C, Raghavendra AS, Amaya D, Ibrahim N, Jing L. Survival outcomes and prognosis for patients with triple negative breast cancer who received stereotactic radiosurgery for brain metastases. San Antonio Breast Cancer Symposium 2020, 2020. PMID: None.
Almeddine HF, Singareeka A, Anderson C, Selfer J, Brewster A, Barcenas CH, Caudle A, Arun B, Ibrahim N. Decision making process and contralateral prophylactic masectomy. San Antonio Breast Cancer Symposium 2020, 2020. PMID: None.
Abuhadra N, Chang CC, Yam C, Sun R, Litton J, Raush G, Thompson A, Lim B, Adrda B, Mittendorf E, Damodaran S, White J, Ravenberg E, Candelaria R, Arun B, Ueno N, Santiago L, Murthy R, Ibrahim N, Sabin A, Huo L, Moulder S, Jeng S. Prospective evaluation of the gut microbiome and response to neoadjuvant therapy (NAT) in early-stage triple negative breast cancer (TNBC). San Antonio Breast Cancer Symposium 2020, 2020. PMID: None.
Kumthekar P, Sahebjam S, Pegram M, Ibrahim, N, Sussell J, Nicholas A, Fung A, ChengA, Lin NU. Patient-reported outcomes following pertuzumab plus high-dose trastuzumab in patients with HER2-positive metastatic breast cancer (MBC) and central nervous system (CNS) progression post-radiotherapy. Neuro-Oncology (SNO) 25th Annual Meeting, 2020. PMID: None.
An R, Wamg U, Gao C, Raghavendra AS, Amaya D, Ibrahim N, Li J. Survival outcomes and prognosis in patients with triple-negative breast cancer and brain metastases. ESTRO 2020, 2020. PMID: None.
Kumthekar P, Sahebjam S, Pegram M, Ibrahim NK, Sussell J, Nicolas A, Tung A, Cheng A, Kirschbrown W, Lin NU. Patient-reported outcomes following pertuzumab plus high-dose trastuzumab in patients with HER2-positive metastatic breast cancer (MBC) and central nervous system (CNS) progression post-radiotherapy. Society of NeuroOncology 2020, 2020. PMID: None.
Kumthekar P, Sahebjam S, Pegram M, Ibrahim NK, Sussell J, Nicholas A, Fung A, Cheng A, Lin NU. Patient-reported outcomes following pertuzumab plus high-dose trastuzumab in patients with HER2-positive metastatic breast cancer (MBC) and central nervous system (CNS) progression post-radiotherapy. Society for NeuroOncology 2020, 2020. PMID: None.
Haven G, Lehner M, Raghavendra AS, Gutierrez-Barrera AM, Tripathy D, Litton JK, Ibrahim N. The incidence and impact of brain metastasis in patients with hereditary BRCA1/2 mutated invasive breast cancer in a prospectively followed cohort. ASCO 2020, 2020. PMID: None.
Lim B, Seth S, Huo L, Layman R, Valero V, oA T, White J, Litton J, Damodaran S, Candelaria R, Arun B, Rauch G, Murthy R, Zhao L, Zhang J, Ding Q, Symmans WF, Ramirez D, Ibrahim N, Thomas P, Moulder S, Ueno NT. Comprehensive profiling of Anddrogen Receptor-Positive (AR+) Triple-Negative Breast Cancer (TNBC) Patients Treated with Standard Neoadjevant Therapy (NAT)+/-Enzalutamide. ASCO 2020, 2020. PMID: None.
Gao C, Raghavendra A, Wang F, Wang Y, An R, Suki D, Heimberger AB, Hsu L, Tripathy D, Li J, Ibrahim NK. Stereotactic radiosurgery with maintained Anti HER2 therapy improves local control and Overall survival in breast cancer patients with brain metastasis. AACR, 2020. PMID: None.
Lin NU, Kumthekar P, Sahebjam S, Ibrahim N, Fung A, Cheng A, Nicholas A, Wang B, Pegram M. Pertuzumab Plus High-Dose Trastuzumab for the Treatment of Central Nervous System Progression After Radiotherapy in Patients. San Antonio Breast Cancer Symposium 2019, 2019. PMID: None.
Abuhadra N, Hess KR, Litton JK, Rauch GM, Thompson A, Lim B, Adrada B, White J, Ravenberg E, Mittendorf E, Damodaran S, Candeleria R, Arun B, Yang WT, Ueno N, Santiago L, Murthy RK, Ibrahim N, Aysegul S, Symmans WF, Moulder S, Huo L. Evaluating the role of mid-treatment tumor infiltrating lymphocytes (TIL) in predicting pathologic complete response (pCR) in early-stage triple negative breast cancer (TNBC). San Antonio Breast Cancer Symposium 2019, 2019. PMID: None.
Raghavendra A, George K, Karam-Hage M, Jizzini M, Seoudy K, Cinciripini P, Ibrahim NK. The Impact of Smoking Cessation on Breast Cancer Patients' Survival. None, 2019. PMID: None.
Abuhadra N, Hess KR, Litton JK, Rauch GM, Thompson AM, Lim B, Adrada BE, Mittendorf EA, Damodaran S, Candelaria R, Arun B, Yang WT, Ueno NT, Santiago L, Murthy RK, Ibrahim NK, Sahin AA, Symmans WF, Moulder SL, Huo L. Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor infiltrating lymphocytes (TIL) receiviing neoadjuvant therapy. ASCO 2019, 2019. PMID: None.
Kumthekar P, Lawrence B, Iordanova V, Ibrahim N, Mazanet R. ANG1005 in leptomeningeal disease (ANGLeD) trial: a randomized, open-label, phase 3 study of ANG1005 compared with Physician's Best Choice in HER2-negative breast cancer patients with newly diagnosed leptomeningeal carcinomatosis and previously treated brain metastases. San Antonio Breast Cancer Symposium 2018, 2018. PMID: None.
Ueno NT, Tahara RK, Reuben JM, Gao H, Saigal B, Fujii T, Lucci A, Ibrahim NK, Damodaran S, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, Lim B, Chasen BA. CTCs and SUV to predict the efficacy of the bone-specific radiopharmaceutical agent radium-223 dichloride combined with hormonal therapy for hormone receptor-positive bone-dominant breast cancer metastasis. San Antonio Breast Cancer Symposium 2018, 2018. PMID: None.
Ueno MT, Tahara RK, Chasen BA, Saigal B, Fujii T, Ibrahim NK, Damodaran S, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, Lim B. Phase II study of Ra-223 combined with hormonal therapy and denosumab for treatment of hormone receptor-positive breast cancer with bone-dominant metastasis. ASCO 2018, 2018. PMID: None.
Litton JK, Scoggins ME, Whitman GJ, Barcenas CH, Moulder S, Murthy, RK, Karuturi MS, Damodaran S, Brewster A, Ibrahim NK, Arun BK, Hess KR, Moulder S, Thompson A, Mittendorf EA, Adrada BE, Schwartz-Gomez J, Rosenstock AS, DeSnyder SM. Neoadjuvant Talazoparib (TALA) for Operable Breast Cancer Patients with a BRCA Mutation (BRCA+). ASCO, 2018. PMID: None.
Tripathy D, Tolane SM, Seidman AD, Anders CK, Ibrahim, NK, Rugo HS, Twelves C, Dieras V, Mueller V, Hannah A, Tagliaferri MA, Cortes J. Phase III study of etirinotecan pegol (EP) vs. treatment of physician's choice (TPC) in patients (pts) witih metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC). ASCO 2018, 2018. PMID: None.
Diab A, Hurwitz ME, Cho DC, Papadimitrakopoulou V, Curti BD, Tykodi SS, Puzanov I, Ibrahim NK, Tolaney SM, Tripathy D, Gao J, Siefker-Radtke AO, Clemens W, Tagliaferri MA, Gettinger SN, Kluger HM, Larkin JMG, Grignani G, Sznol M, Tannir NM. NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumores: Preliminary phase I/2 results of PIVOT. ASCO 2018, 2018. PMID: None.
Tahara RK, Fujii T, Saigal B, Ibrahim NK, Damodaran S, Barcenas CH, Murray JL, Chasen BA, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, Ueno NT. Phase II study of the feasibility and safety of radium-223 dichloride in combination with hormonal therapy and denosumab for the treatment of patients with hormone receptor-positive breast cancer with bone-dominant metastasis. 2017 CTRC-AACR San Antonio Breast Cancer Symposium, 2017. PMID: None.
Abdulrrahman B, Hess K, Ibrahim NK. Statistical model to predict brain metastasis risk in patients with early-stage breast cancer. ESMO 2017. Travel Award-wining, 2017. PMID: None.
Bashour SI, Ibrahim NK, Schomer DF, Colen RR, Sawaya R, Suki D, Rao G, Murthy RK, Moulder SL, Abugabal Y, Hess KR, Fuller GN. Central Nervous System Miliary Metastasis in Breast Cancer Patients. SABCS 2017 Poster Presentation, 2017. PMID: None.
Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim NK, Rugo HS, Twelves C, Dieras V, Müller V, Hannah A, Tagliaferri M, Cortés J. ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC). 2017 ASCO Annual Meeting, 2017. PMID: None.
Weiss A, Bashour S, Hsu L, Hess KR, Thompson AM, Ibrahim NK. Effect of neoadjuvant chemotherapy regimen choice in patients with breast cancer with pathologic complete response. 2017 ASCO Annual Meeting Poster Discussion Travel/Award-Winning, 2017. PMID: None.
Pant S, Wheler JJ, Fu S, Hong DS, Karp DD, Subbiah V, Tsimberidou AM, Holley VR, Brewster AM, Koenig KH, Ibrahim NK, Murthy RK, Meric-Bernstam F, Janku F. Proof-of concept phase I study of everolimus, letrozole and trastuzumab in hormone receptor-positive, HER2-positive/amplified or mutant metastatic breast cancer or other solid tumors: Evaluating synergy and overcoming resistance. 2017 ASCO Annual Meeting, 2017. PMID: None.
Ibrahim NK. ATTAIN Study: Phase 3 study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine. ASCO 2017, 2017. PMID: None.
Lin NU, Stein A, Nicholas A, Fung AM, Kumthekar P, Ibrahim NK, Pegram MD. Planned interim analysis of PATRICIA: An open-label, single-arm, phase II study of pertuzumab (P) with high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression post radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC). 2017 ASCO Annual Meeting, 2017. PMID: None.
Ibrahim NK, Tang SC, Brenner A, Kesari S, Prccioni D, Anders C, Carrilo J, Chalasani P, Kabos P, Puhalla S, Garcia A, Tkaczuj K, ahluwalia AS, Lakhani N, Kumthekar P. A phase II, open-label, multi-center study of ANG1005, a novel brain-penetrant peptide-drug conjugate, in breast cancer patients with recurrent CNS metastases. 2016 San Antonio Breast Cancer Symposium, 2016. PMID: None.
Tripathy D, Tolaney S, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves CJ, Cortés J. Phase 3 Study of Etirinotecan Pegol versus Treatment of Physician’s Choice in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases Previously Treated With an Anthracycline, a Taxane, and Capecitabine. 2016 San Antonio Breast Cancer Symposium, 2016. PMID: None.
Kumthekar P, S-C T, Brenner A, Kesari S, Piccioni D, Anders C, Carrillo J, Chalasani P, Kabos P, Puhalla S, Garcia A, Tkaczuk K, Ahluwalia MS, Lakhani N, Ibrahim NK. A Novel Brain-Penetrant Taxane Derivative, for the Treatment of Recurrent Brain Metastases and Leptomeningeal Carcinomatosis from Breast Cancer. 2016 ASCO Annual Meeting, 2016. PMID: None.
S-C T, Kumthekar P, Brenner AJ, Kesari S, D Piccioni D, Anders CK, Carillo JA, Chalasani P, Kabos P, Puhalla SL, Garcia A, Tkaczuk K Ahluwalia MS, Lakhani N, NK I. ANG1005, a novel peptide-paclitaxel conjugate crosses the BBB and shows activity in patients with recurrent CNS metastasis from breast cancer, results from a Phase II Clinical Study. European Society for Medical Oncology, 2016. PMID: None.
Kumthekar P, Tang SC, Brenner A, Kesari S, Anders C, Carrillo J, Chalasani P, Kabos P, Ahluwalia M, Ibrahim N. A Phase II Study of ANG1005, a novel BBB/BCB Penetratant Taxane in Patients with Recurrent Brain Metastases and Leptomeningeal Carcinomatosis from Breast Cancer. EANO, 2016. PMID: None.
Kumthekar P, Bates S, Kesari S, Brenner A, Anders C, Garcia A, Ibrahim N, Tkaczuk K, Tang SC. ANG1005, a novel brain-penetrant peptide-taxane conjugate, for the treatment of CNS metastases from breast. (Poster Presentation). Proc from 20th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology, 2015. PMID: None.
Chen S, Ibrahim NK, Wong S, Wang H, Wong FC. Prognostic value of metabolic complete response on 18F-FDG PET/CT in stage II or III breast cancer patients. Proc. from Socitey of Nuclear Medicine and Molecular Imaging 2015, 2015. PMID: None.
Chen S, Ibrahim NK, Wong S, Wang H, Wong FC. Risk stratification in patients with newly diagnosed stage III or IV breast cancer by metabolic parameters of. Proc. from Society of Nuclear Medicine and Molecular Imaging 2015, 2015. PMID: None.
Mitri Z, Nanda R, Blackwell K, Costello C, Hood I, Brewster A, Ibrahim N, Koenig K, Hortobagyi G, Van Poznak K, Rimawi M, Moulder S. TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid (ZA) for the Treatment of Breast Cancer Bone Metastasis (MBC-bone). (Poster Presentation). 2015 ASCO Annual Meeting, 2015. PMID: None.
Moulder S, Ueno NT, Yang W, Enso J, Valero V, Litton JK, Murthy R, Ibrahim N, Arun B, Mittendorf B, Hunt K, Meric-Bernstam F, Thompson A, Piwnica-Worm H, Tripathy D, Symmans F. Women’s Triple-negative, First-line treatment: Improving outcomes in triple-negative breast cancer (TNBC) using molecular triaging and diagnostic imaging to guide neoadjuvant therapy (NACT). (Poster Presentation). 2015 ASCO Auunual Meeting, 2015. PMID: None.
Mittendorf EA, Schneble EJ, Ibrahim NK, Greene JM, Berry JS, Trappey AF, Clifton GT, Holmes JP, Ponniah S, Peoples GE. Combination immunotherapy with trastuzumab and the HER2 vaccine E75 (nelipepimut-S) in high-risk HER2+ breast cancer patients to prevent recurrence. (Poster Presentation). Proc. from 2014 SABCS, 2014. PMID: None.
Shen Q, Ibrahim N, Aldape K, Sahin A. Breast cancer with brain metastases: risk factors and survival. (Oral Presentation). Accepted at the 102nd US and Canadian Academy of Pathology annual meeting, 2013. PMID: None.
Heery C, Gulley J, Ibrahim N. A phase 2 randomized trial of docetaxel alone or in combination with therapeutic cancer vaccine, CEA-, MUC-1-TRICOM (Poster Presentation). European Society for Medical Oncology (ESMO), 2012. PMID: None.
Dean-Colomb WM, Hess KR, Young EJ, Gornet TG, Handy B, Moulder SL, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Evaluation of circulating biomarkers of bone metastasis in early-stage breast cancer. American Society of Clinical Oncology (ASCO). e-Pub 2012. PMID: None.
Lousquy R, Delpech Y, Rouzier R, Gilgorov J, Hsu L, Barranger E, Pusztai L, Uzan S, Hortobagyi GN, Coutant C, Ibrahim N. Nomogram to predict bone metastasis in patients with non metastatic breast carcinomas; Poster Presentation. San Antonio Breast Cancer Symposium, San Antonio, TX, 2011. PMID: None.
Kelly CM, Green MC, Broglio K, Pusztai L, Thomas E, Brewster A, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Hunt K, Hortobagyi GN, Buzdar A. Capecitabine in operable triple receptor–negative breast cancer: A subgroup analysis of a randomized phase III trial. (Poster Presentation) ASCO 2011, 2011. PMID: None.
Gonzlaez-Angulo AM, Green MC, Murray JL, Palla SL, Koeniq KH, Brewster AM, Valero V, Ibrahim NK, Moulder SL, Litton JK, Crawford DJ, Flores PR, Dryden MJ, Symmans WF, Giordano SH, Pusztai L, Buzdar A, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC). (Poster Presentation) ASCO 2011, 2011. PMID: None.
Raghav KPS, Bekele BN, Valero V, Ibrahim NK. Nomogram for predicting development of brain metastasis in patients with inflammatory breast cancer. (Poster Presentation) ASCO 2011, 2011. PMID: None.
Vasaikar S, Seth S, Hollander PD, Guaine R, Beatriz A, Candelaria R, Mittendorf E, Thompson A, Litton J, Lim B, Arun B, Ueno NT, Valero V, Ibrahim N, Murthy R, Damodaran S, White J, Tripathy D, Piwnica-Worms H, Symmans WF, Change J, Mani S, Moulder SL. Therapeutic Strategies (Neoadjuvant Chemotherapy). San Antonio Breast Cancer Symposium 2019, 2010. PMID: None.
Garber HR, Rauch GM, Adrada BE, Candelaria RP, Mittendorf EA, Thompson AM, Litton JK, Damodaran S, Lim B, Arun BK, Ueno NT, Valero V, Ibrahim NK, Murthy RK, White JB, Tripathy D, Piwnica-Worms H, Symmans WF, Huo L, Moulder SL. Residual Cancer Burden in Patients with Early Stage Triple Negative Breast Cancer who Progress on Anthracycline-based neoadjuvant chemotherapy in an Ongoing Clinical Trial (ARTEMIS). San Antonio Breast Cancer Symposium 2019, 2010. PMID: None.
Ibrahim N, Wong L, Stopeck A, Rosen LS, Gerber DE, Shan JS. Phase 1 study of bavituximab in advanced solid tumor malignancies: Final results. (Poster Discussion), 2010 AACR 101st Annual Meeting, 2010. PMID: None.
Buzdar A, Valero V, Ibrahim NK, Theriault RL, Pusztai L, Green MC, Hunt KK, Esteva FJ, Ewer MS, Hortobagyi GN. Seventy-two month update of randomized trial of preoperative therapy of paclitaxel follwed by 5-fluourouracil, epirubicin, and cyclophosphamide chemotherapy with or without concurrent trastuzumab in human epidermal growth factor receptor-2 positive operable breast cancer. Temporary abstr #400454. Breast Cancer Symposium, San Francisco, CA, 2009. PMID: None.
Pustzi L, Rouzier R, Ibrahim N. A nomogram to predict subsequent brain metastasis in metastatic breast cancer (MBC) patients. American Soceity of Clinical Oncology (ASCO) 27, 2009. PMID: None.
Buzdar AU, Green MC, Broglio KR, Carter CD, Valero V, Ibrahim NK, Hunt KK, Hortobagyi GN. Prospecitve randomized trial evaluating weekly paclitaxel (WP) versus docetaxel in combination with capecitabine (DC) in operable breast cancer. Poster #542. American Society of Clinical Oncology (ASCO) 27, 2009. PMID: None.
Ibrahim NK, Wong L, Rose L, Shan J. Phase I study of bavituximab, a novel anti-phosphatidylserine monoclonal antibody in patients with advanced refractory cancer: preliminary results. Poster #1080. American Society of Clinical Oncology (ASCO) 27, 2009. PMID: None.
Pusztai L, Rouzier R, Ibrahim NK. A specific nomogram to predict subsequent brain metastasis in metastic triple-negative breast cnacer patients. (Poster Presentation) ASCO 2009, 2009. PMID: None.
Ibrahim N, Abdulkarim B, Huguet F, Gabos Z, Hsu L, Marpeau O, Uzan S, Pusztai L, Strom E, Hortobagyi GN, Rouzier R. A nomogram to predict subsequent brain metastasis in metastatic breast cancer (MBC) patients. European Society for Medical Oncology (ESMO), 2008. PMID: None.
Ibrahim N, Abdulkarim B, Huguet F, Gabos Z, Hsu L, Marpeau O, Uzan S, Pusztai L, Strom E, Hortobagyi GN, Rouzier R. A nomogram to predict subsequent brain metastasis in metastatic breast cancer (MBC) patients. American Society of Clinical Oncology (ASCO) 26, 2008. PMID: None.
Pusztai L, Hess K, Anderson K, Valero V, Ibrahim N, Meija M. Pharmacogenomic predictor of complete response to preoperative paclitaxel and 5-fluorouracil, doxorubicin, cyclophosphamide chemotherapy in breast cancer. American Society of Clinical Oncology (ASCO) 25, 2006. PMID: None.
Ibrahim N, Nguyen G, Suki D, Montero J, Sarriera, Symmans W, Valero V, Sawaya R, Aldape K. Clinicopathological correlation and outcome of breast cancer patients with resected brain metastasis (Poster presentation). American Society of Clinical Oncology (ASCO) 25, 2006. PMID: None.
Moussallem C, Lopez A, Gauthier A, Moore S, Johnson M, Murray J, Ibrahim N. Fulvestrant (F) in metastatic breast cancer: Standard dose (Std) vs loading dose (Ld) A retrospective study. American Society of Clinical Oncology (ASCO) 2006 25, 2006. PMID: None.
Borges V, Ibrahim N, Shapiro CL, ESl P. Phase I pharmacokinetics (PK) of humanized anti-MUC-1 antibody R1550. American Society of Clinical Oncology (ASCO) 25, 2006. PMID: None.
Ibrahim NK. Neoadjuvant Chemotherapy in Breast Cancer: Many Approaches, Common Target. Congrès Oncologie Moyent-Orient (COMO) IIV Abstract, 2005. PMID: None.
Hanrahan EO, Hortobagyi GN, Valero V, Booser D, Brewster A, Cristofanilli M, Esteva F, Ibrahim N, Murray J, Rosales M, Royce M, Rivera E. Phase II study of docetaxel in patients with stage IV NED breast cancer who have failed prior anthracycline-based chemotherapy. International Congress on Anti Cancer Treatment (ICACT), 2005. PMID: None.
Murray JL, Kawano K, Efferson C, Babiera G, Meric-Bernstram F, Ibrahim N, Kallinteris NL, et al. Enhanced HER2/neu specific T-cell immunity in vitro by HER2/neu li-key modified agonist class II peptides in breast cancer patients. San Antonio Breast Cancer Symposium (SABCS) 99, 2005. PMID: None.
Buzdar AU, Valero V, Ibrahim N, Francis D, Theriault RL, Green M, et al. Prospective data of additional patients treated with Neoadjuvant therapy with paclitaxel followed by FEC chemotherapy with trastuzumab in Her-2 positive operable breast cancer, and an update of initial study population. San Antonio Breast Cancer Symposium (SABCS) 99, 2005. PMID: None.
Ibrahim NK, Murray J, Parker J, Finke L, Miles D. Humoral immune- response to naturally occurring STn in metastatic breast cancer patients (MBC pts) treated with STn-KLH vaccine (poster presentation). American Society of Clinical Oncology (ASCO) 23:174, 2004. PMID: None.
Miles D, Cameron D, Dodwell D, Glaspy J, Guillem V, Ibrahim NK, Martin M, Perren T, Roche H, Tres A, Study Group FT. Pre-treatment chemotherapy (CX) regimens and responses in 1028 metastatic breast cancer (MBC) patients from an international, randomized phase III clinical trial of STn-KLH therapeutic vaccine. American Society of Clinical Oncology (ASCO) 22:55, 2003. PMID: None.
Royce M, Ibrahim N, Symmans WF, Blumenstein G, Declassed ES, Crocker SA, Steiner J, Boniface G, Hortobagyi GN, Pusztai L. Phase II study to evaluate tagretin (XR9576), a selective MDR-1 inhibitor, in chemotherapy resistant advanced breast cancer. American Society of Clinical Oncology (ASCO) 22:29, 2003. PMID: None.
Ibrahim NK, Macneil S, Headley JA, Bisotooni KT, Buzdar AU, Hortobagyi GN. Effect of paclitaxel (P)-based chemotherapy on the ovarian failure (OF) of breast cancer patients (pts): A retrospective study. (Poster presentation). American Society of Clinical Oncology (ASCO) 22:753, 2003. PMID: None.
Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales M, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault R, Carter C, Singletary SE, Kuerer HM, Hunt K, Strom E, Hortobagyi GN. Weekly paclitaxel followed by FAC as primary systemic chemotherapy of operable breast cancer improves pathologic complete remission rates when compared to every 3-week P therapy followed by FAC, final results of a prospective phase III randomized trial. Proc American Society of Clinical Oncology (ASCO):35, 2002. PMID: None.
Li Z, Ibrahim NK, Wang M, Valero V, Theriault RL, Buzdar AU, Hortobagyi GN. Colitis in breast cancer patients treated with taxane-based chemotherapy: M. D. Anderson Cancer Center experience (poster presentation). Proc American Society of Clinical Oncology (ASCO) 21:57a, 2002. PMID: None.
Ibrahim NK, Samuels B, Page R, Guthrie T, Ramakrishnan G, Doval D, Patel K, Rao S, Nair M, Digumarti D, Hortobagyi GN. Nanoparticle paclitaxel (ABI-007) in metastatic breast cancer: efficacy and evidence of dose-dependent activity in two multicenter phase II studies (poster presentation). Proc American Society of Clinical Oncology (ASCO) 22:53, 2002. PMID: None.
Ibrahim NK, Ellerhorst JA, Theriault RL, Rivera E, Esmaeli B, Ring SE, Soon-Shiong P, Benjamion RS, Hortobagyi GN. Phase I study of cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel (ABI-007) in solid tumors. (Poster presentation). American Society of Clinical Oncology (ASCO) 19, 2000. PMID: None.
Valero V, Esteva FJ, Rosales MF, Guerra LT, Sahin AA, Strom EA, Ross MI, Booser DJ, Ibrahim NK, Cristofanilli M, Hunt KK, Hortobagyi GN. Phase II trial of primary chemotherapy with docetaxel and doxorubicin in locally advanced breast cancer: clinical and pathological results. American Society of Clinical Oncology (ASCO) 19:132a, 2000. PMID: None.
Thomas E, Buzdar A, Theriault R, Singletary S, Booser D, Valero V, Ibrahim N, Smith T, Frye D, Manuel N, S-W K, McNeese M, Strom E, Hunt K, Ames F, Hortobagyi G. Role of paclitaxel in adjuvant therapy of operable breast cancer: preliminary results of prospective randomized clinical trial. American Society of Clinical Oncology (ASCO) 19, 2000. PMID: None.
Fornage BD, Edeiken BS, Bedi D, Singletary SE, Ibrahim NK, Strom EA. Sonographically guided implantation of metallic markers for localization of the tumor bed in breast cancer patients undergoing preoperative chemotherapy. (Oral presentation). Am Institute Ultrasound Med, 2000. PMID: None.
Li Z, Wang M, Mente R, Ibrahim N. Taxane-based chemotherapy-induced colitis in breast cancer patients: M. D. Anderson Cancer Center experience. (Poster presentation). 23rd Annual San Antonio Breast Cancer Symposium (SABCS) 64 (1):84, 2000. PMID: None.
Asmar L, Ibrahim NK, Buzdar AU, Smith TL, Theriault RL, Hortobagyi GN. Doxorubicin by continuous infusion vs bolus infusion in metastatic breast cancer: impact on time-to-progression, M. D. Anderson Cancer Center experience. (Poster presentation). American Society of Clinical Oncology (ASCO) 19:105a, 2000. PMID: None.
Michaud LB, Gauthier MA, Wojdylo JR, Valero V, Theriault RL, Ibrahim NK, Hortobagyi GN. Improved therapeutic index with lower dose capecitabine in metastatic breast cancer patients. (Poster presentation). American Society of Clinical Oncology (ASCO) 19:104a, 2000. PMID: None.
Kozuch P, Ibrahim N, Khuri F, Hoff P, Estey E, Gandhi V, Du M, Rios MB, Plunkett W, Keating MJ, Kantargian H. Phase I clinical and pharmacological study of clofarabine. (Poster presentation). Am Soc Hemat, 1999. PMID: None.
Buzdar AU, Hortobagyi GN, Theriault RL, Booser DJ, Valero V, Ibrahim N, Asmar L, Frye D, Manuel N, Kau S, McNeese M, Strom E, Hunt K, Singletary E, Ames F. Prospective randomized trial of Taxol alone versus fluorouracil, doxorubicin, cyclophosphamide (FAC) as an induction therapy in patients with operable breast cancer. Proc American Society of Clinical Oncology (ASCO) 18:73a, 1999. PMID: None.
Anderson B, Lu J, Ibrahim N, Hortobagyi G, Brewer H, Przepiorka D, Ioannides C, Brabstein K, Cheever M, Murray J. Immunomodulating effects of a HER2/neu derived HLA-A2 specific peptide E75 combined with GM-CSF in patients with metastatic breast and ovarian cancer. Proc American Society of Clinical Oncology (ASCO) 18:436a, 1999. PMID: None.
Edeiken BS, Fornage BD, Bedi D, Singletary SE, Ibrahim NK, Strom EA. Sonographically guided implantation of metallic markers for localization of the tumor bed in breast cancer patients undergoing preoperative chemotherapy. Am Institute Ultrasound Med, 1999. PMID: None.
Ibrahim NK, Willey J, Rahman Z, Valero V, Hortobagyi GN. Phase II study of vinorelbine by 96-hour continuous infusion for patients with metastatic breast cancer. Proc American Society of Clinical Oncology (ASCO) 17:113, 1998. PMID: None.
Ueno NT, Hung MC, Zhang S, Xia W, Willey JS, Warner DL, Payne JY, Nandagiri R, Aldridge R, De Jager RL, Rucker S, Putnam JB, Sneige N, Katz RL, Spohn WH, Bast RC, Holmes FA, Ibrahim NK, Theriault RL, Rahman ZU, Valero V, Kudelka AP, Kavanagh JJ, Freedman RS, Wolf JK, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hortobagyi GN. Phase I E1A gene therapy in patients with advanced breast and ovarian cancers. Proc American Society of Clinical Oncology (ASCO) 17:432a, 1998. PMID: None.
Willey J, Ibrahim NK, Walters R, Rahman Z, Valero V, Esteva FJ, Hortobagyi GN. Vocal cord paralysis secondary to biweekly vinorelbine (Navelbine®) and paclitaxel (Taxol®) by simultaneous 3-hour infusion with G-CSF support as frontline therapy for metastatic breast cancer patients. Proc American Society of Clinical Oncology (ASCO) 17:183, 1998. PMID: None.
Valero V, Esparza-Guerra L, Rahman Z, Ibrahim N, Booser D, Patel S, Holmes FA, Qasim M, Hoff P, Bellet R, Hortobagyi G. Phase I Study of Docetaxel (Taxotere) and Cyclophosphamide without and with G-CSF in Previously Treated and Untreated Solid Tumors. Proc American Society of Clinical Oncology (ASCO) 16:220a, 1997. PMID: None.
Hoff PM, Valero V, Ibrahim NK, Willey J, Hortobagyi G. Prolonged Infusion of Vinorelbine Causing Hand-Foot Syndrome. Proc American Society of Clinical Oncology (ASCO) 16:238a, 1997. PMID: None.
Ibrahim NK, Hortobagyi GN, Valero V, Walters R, Willey J, Buzdar AU. Phase I Study of Vinorelbine (NVB; Navelbine) and Paclitaxel(PTX; Taxol) by simultaneous (sim) 3-hour (H) infusion (inf), with G-CSF support, for Untreated Metastatic Breast Cancer(MBC). San Antonio Breast Cancer Symposium (SABCS) Poster Presentation 37 Supplement:44, 1996. PMID: None.
Ibrahim NK, Hortobagyi GN, Valero V, Theriault R, Willey J. Phase I Study of Vinorelbine (NVB; Navelbine) and Paclitaxel(PTX; Taxol) by simultaneous (sim) 3-hour (H) infusion (inf), with G-CSF support, for Untreated Metastatic Breast Cancer(MBC) Poster Presentation. 18th Annual San Antonio Breast Cancer Symposium (SABCS), 1995. PMID: None.
Ibrahim NK, Frye D, Buzdar AU, Fraschini G, Hortobagyi GN. Risk of Doxorubicin (D)-Related Cardiac Morbidity in Elderly Patients (pts) with Metastatic Breast Cancer (poster presentation). Proc American Society of Clinical Oncology (ASCO) 14:95, 1995. PMID: None.
Ibrahim NK, Hortobagyi G, Valero V, Dhingra K, Willey J, Hohnekar J, Buzdar AU. Phase I Study of Vinorelbine (NVB; Navelbine) and Paclitaxel(PTX; Taxol) by simultaneous (sim) 3-hour (H) infusion (inf), with G-CSF support, for Untreated Metastatic Breast Cancer(MBC) (poster presentation). Proc of the American Association for Cancer Research(AACR) 36:242, 1995. PMID: None.
Ibrahim NK, Buzdar A, Frye D, Hortobagyi G. Should Age Be a Determinant Factor in Treating Breast Cancer Patients with Combination Chemotherapy? Oral Presentation. Proc American Society of Clinical Oncology (ASCO):68, 1993. PMID: None.
Abuhadra N, Chang CC, Yam C, White JB, Ravenberg E, Lim B, Ueno NT, Litton JK, Arun B, Damodaran S, Murthy RK, Ibrahim NK, Hortobagyi GN, Valero V, Tripathy D, Thompson AM, Mittendorf EA, Huo L, Moulder SL, Jenq RR. The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC). ASCO 2021. PMID: None.
Raghavendra AS, Chao G, Fuchenchu W, An R, Wang Y, Suki D, Heimberger AB, Tripathy D, Li J, NK <. Stereotactic radiosurgery (SRS) for brain metastasis (BM) in hormone receptor positive (HR+) HER2 negative breast cancer (BC). ASCO 2021. PMID: None.
Ibrahim N, Kim SB, Lin NU, Awada A, Gil EC, Tonini G, Vallespir BP, Theall KP, Hamilton E. ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC). SABCS. PMID: None.
Abuhadra N, Chang CC, Yam C, Whiite J, Ravenberg E, Lim B, Ueno N, Litton J, Arun B, Damodaran S, Murthy RK, Ibrahim NK, Hortobagyi G, Valero V, Tripathy D, Thompson AM, Mittendorf E, Huo L, Moulder SL, Jenq RR. The impact of gut microbial composition on response to neoadjuvant. ASCO 2021. PMID: None.
Piha-Paul SA, Xu B, Fan Y, Yuan Y, Lavasani S, Mortimer J, Goel S, Tsimberidou S, Ibrahim N, Abouharb S, Barcenas CH, Ilheme AN, Karp DD, Rodon J, Dumbrava EE, Fan J, Peng P, Sun C, Wang H, Hennessy K, Fu X, Xu R, Ni S, Wu F, Meric-Bernstam. The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2- breast cancer or TNBC. SABCS. PMID: None.
Ibrahim NK, Hamilton EP, Kim SB, Im YH, Segu E, Garcia-Saenz JA, Sanzo AD, Vallespir BP, Dominguez M, Wasserman T, Theall KP, Ciruelos E. Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase 1b/2 study. 2024 ASCO Annual Meeting. PMID: None.
Ibrahim, Nuhad K. Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase 1b/2 study. 2024 ASCO Annual Meeting. PMID: None.
Raghavendra AS, Gao C, Weng F, An R, Wang Y, Suki R, Hermberger AB, Tripathy D, Li J, Ibrahim NK. Stereotactic radiosurgery (SRS) for brain metastasis (BM) in hormone receptor positive (HR+) HER2 negative. ASCO 2021. PMID: None.
Raghavendra AS, Kotecki N, Jennings K, Amato O, Tripathy D, Ahmad A, Ibrahim NK. Nomogram for predicting brain metastasis in early-stage breast cancer patients. SABCS 2023. PMID: None.

Book Chapters

Tripathy D, Makhnoon S, Arun B, Sahin A, Kettner NM, Damodaran S, Keyomarsi K, Yang W, HUnt KK, Clemens M, Woodward WA, Mitchell MP, Layman R, Hobbs EA, Lim B, Dupuis M, Murthy R, Alhalabi O, Ibrahim N, Subbiah IS, Barcenas C. Neoplasms of the Breast. In: Holland-Frei Cancer Medicine. Tenth. Wiley Blackwell, 1361-1412, 2023.
Pestana RC, Ibrahim NK. Cancer Treatment Modalities Systemic and Locoregional approaches: Challenges and Opportunities of Multidisciplinary Approaches. In: Locoregional Radionuclide Cancer Therapy. None. Springer Nature, 17-37, 2021.
Yang C, Zhang L, Murray JL, Ibrahim NK. MUC1 and Cancer Immunotherapy. In: Immunology: Immunotoxicity, Immunopathology, and Immunotherapy. Chapter 15. Elsevier, 225-240, 2018.
Bashour SI, William WN, Patel S, Rao G, Strom E, McAleer MF, Guha-Thakurta N, Conrad C, Ibrahim NK. Brain metastasis from solid tumors. In: Brain Metastases from Primary Tumors: Epidemiology, Biology, and Therapy. 1. Elsevier/Academic Press, 3-29, 2015.
Matrana MR, Ibrahim N. Brain-only metastatic breast cancer is a distinct clinical entity characrterised by favourable median overall survival time and a high rate of long-term survivors. In: Breast Diseases: A Year Book Quarterly. 3. None, 224-25, 2013.
Shonka NA, NKb I, Groves MD. Management of central nervous system metastases in breast cancer. In: Advanced Therapy of Breast Disease. None. None, 2012.
Barcenas CH, Ibrahim NK. Chemotherapy-Induced Colitis. In: Colitis. None. Intech, 2012.
Matrana MR, Ibrahim NK. Breast cancer metastasis to the central nervous system. In: Tumors of the Central Nervous System. None. Springer, 35-49, 2012.
Ibrahim NK, Hortobagyi GN. Metastatic carcinoma of the breast (stage IV). In: The Practice of General Surgery. None. W. B. Saunders, 2002.
Pinto AC, Lambertini M, Azim HA, Awada A, Ibrahim NK. Breast Cancer and Pregnancy. In: Maternal Medicine. None. McGraw Hill.
Ibrahim NK, Litton JK. Special Clinical Situations in Patients with Breast Cancer. In: Breast Cancer. 4th. None.

Letters to the Editor

Nancy UL, Pegram M, Sahebjam S, Ibrahim NK, Fung A, Cheng A, Nicholas A, Kirschbrown W, Kumthekar P. Reply to J. Wei et al. Journal of Clinical Oncology 39: 4127-4128, 2021.
Coomes EA, Al-Shamsi HO, Meyers BM, Alhazzani W, Alhuraiji A, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Elfiki T, Curigliano G, Eng C, Grothey A, Xie C. In Reply. Oncologist.
Ibrahim NK. Response to comments on Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M. D. Anderson experience, with long-term follow up. Ann Oncol 12: 1181, 2001.
Ibrahim NK. Colitis associated with docetaxel-based chemotherapy. Lancet 355: 1824, 2000.

Less

Grant & Contract Support

Title:	An Open-label Multicenter Phase 1b-2 Study of Elacestrant as Monotherapy and in Combination with Abemaciclib in Women and Men with Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer (ELECTRA)
Funding Source:	Stemline Therapeutics
Role:	PI

Title:	START UP ONLY: An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination with Onapristone in Patients with Estrogen Receptor-Positive, Progesterone Receptor-Positive, HER2-negative Advanced or Metastatic Breast Cancer (ELONA)
Funding Source:	Context Therapeutics Inc
Role:	PI

Title:	Strategic Alliance: A Phase 1/2, Open-Label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or The Combination of NKTR-214, Nivolumab, and Ipilimumab in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies
Funding Source:	Nektar Therapeutics
Role:	PI

Title:	Phase 3 Open- Label, Randomized, Multicenter Study Of NKTR-102 Versus TPC In Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases And Have Been Previously Treated With An Anthracycline, A Taxane, and Capecitabine
Funding Source:	Nektar Therapeutics
Role:	PI

Title:	NO TITLE PROVIDED
Funding Source:	Mr. and Mrs. Merrill D. Wynne
Role:	PI

Title:	NO TITLE PROVIDED
Funding Source:	Susan Mintz Philanthropy for Breast Clinical research and Education
Role:	PI

Title:	Multiple genetic alterations in breast cancer
Funding Source:	Department of the Army, U. S. Army Medical Research
Role:	Collaborator

Title:	NO TITLE PROVIDED
Funding Source:	MD Anderson Cancer Center Fellow's Research Grant Award
Role:	Collaborator

CV information above last modified December 18, 2024

Nuhad K. Ibrahim

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Manuals, Teaching Aids, Other Teaching Publications

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Grant & Contract Support

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Nuhad K. Ibrahim

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Manuals, Teaching Aids, Other Teaching Publications

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer